Organization
Legend Biotech
3 clinical trials
Clinical trial
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-12-01